Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096028 | 1.00 | FAAH (0.68) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL28896859 | 1.00 | FAAH (0.68) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL24624954 | 1.00 | FAAH (0.68) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL24624692 | 1.00 | FAAH (0.68) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL20381652 | 1.00 | FAAH (0.68) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL17710357 | 0.92 | FAAH (0.69) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL21682798 | 0.92 | FAAH (0.69) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL19513937 | 0.92 | FAAH (0.69) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL20801622 | 0.92 | FAAH (0.69) | FAAHDNM1CASP2NAAAHSP90AA1 | |
| SCHEMBL15463170 | 0.92 | FAAH (0.69) | FAAHDNM1CASP2NAAAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245069-A2 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023069733-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3687509-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION | Aquestive Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3687510-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067670-A1 | ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS | AQUESTIVE THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019067667-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION | AQUESTIVE THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-3452024-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION | Aquestive Therapeutics, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3452023-A1 | ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS | Aquestive Therapeutics, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192923-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION | MONOSOL RX, LLC (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192921-A1 | ENHANCED DELIVERY EPINEPHRINE COMPOSITIONS | MONOSOL RX, LLC (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2008081348-A2 | METHOD AND COMPOSITION FOR PERMANENTLY SHAPING HAIR | THE PROCTER & GAMBLE COMPANY (US) | 2008-07-10 | — | — | WO | disclosed |